These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35871396)

  • 1. Implementation of International Prognostic Index with flow cytometry immunophenotyping for better risk stratification of chronic lymphocytic leukemia.
    Giudice V; Serio B; Bertolini A; Mettivier L; D'Alto F; Pezzullo L; D'Addona M; Fumo R; Zeppa P; Gorrese M; Selleri C
    Eur J Haematol; 2022 Nov; 109(5):483-493. PubMed ID: 35871396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Gooden CE; Jones P; Bates R; Shallenberger WM; Surti U; Swerdlow SH; Roth CG
    Cytometry B Clin Cytom; 2018 Jan; 94(1):129-135. PubMed ID: 27221715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD49d and CD26 are independent prognostic markers for disease progression in patients with chronic lymphocytic leukemia.
    Ibrahem L; Elderiny WE; Elhelw L; Ismail M
    Blood Cells Mol Dis; 2015 Aug; 55(2):154-60. PubMed ID: 26142332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia.
    Gattei V; Bulian P; Del Principe MI; Zucchetto A; Maurillo L; Buccisano F; Bomben R; Dal-Bo M; Luciano F; Rossi FM; Degan M; Amadori S; Del Poeta G
    Blood; 2008 Jan; 111(2):865-73. PubMed ID: 17959854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.
    Majid A; Lin TT; Best G; Fishlock K; Hewamana S; Pratt G; Yallop D; Buggins AG; Wagner S; Kennedy BJ; Miall F; Hills R; Devereux S; Oscier DG; Dyer MJ; Fegan C; Pepper C
    Leuk Res; 2011 Jun; 35(6):750-6. PubMed ID: 21093051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.
    Baumann T; Delgado J; Santacruz R; Martínez-Trillos A; Rozman M; Aymerich M; López C; Costa D; Carrió A; Villamor N; Montserrat E
    Br J Haematol; 2016 Jan; 172(1):48-55. PubMed ID: 26559905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia.
    Zucchetto A; Bomben R; Dal Bo M; Sonego P; Nanni P; Rupolo M; Bulian P; Dal Maso L; Del Poeta G; Del Principe MI; Degan M; Gattei V
    J Cell Physiol; 2006 May; 207(2):354-63. PubMed ID: 16331666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.
    Bulian P; Shanafelt TD; Fegan C; Zucchetto A; Cro L; Nückel H; Baldini L; Kurtova AV; Ferrajoli A; Burger JA; Gaidano G; Del Poeta G; Pepper C; Rossi D; Gattei V
    J Clin Oncol; 2014 Mar; 32(9):897-904. PubMed ID: 24516016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential.
    Shanafelt TD; Geyer SM; Bone ND; Tschumper RC; Witzig TE; Nowakowski GS; Zent CS; Call TG; Laplant B; Dewald GW; Jelinek DF; Kay NE
    Br J Haematol; 2008 Mar; 140(5):537-46. PubMed ID: 18275431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort.
    Rani L; Gogia A; Singh V; Kumar L; Sharma A; Kaur G; Gupta R
    Ann Hematol; 2019 Feb; 98(2):437-443. PubMed ID: 30338367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells.
    Zucchetto A; Vaisitti T; Benedetti D; Tissino E; Bertagnolo V; Rossi D; Bomben R; Dal Bo M; Del Principe MI; Gorgone A; Pozzato G; Gaidano G; Del Poeta G; Malavasi F; Deaglio S; Gattei V
    Leukemia; 2012 Jun; 26(6):1301-12. PubMed ID: 22289918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.
    Strati P; Parikh SA; Chaffee KG; Achenbach SJ; Slager SL; Call TG; Ding W; Jelinek DF; Hanson CA; Kay NE; Shanafelt TD
    Br J Haematol; 2017 Jul; 178(1):99-105. PubMed ID: 28386906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma.
    Balakrishna J; Basumallik N; Matulonis R; Scott D; Salem D; Jasper G; Wiestner A; Stetler-Stevenson M; Marti G; Sun C; Yuan CM
    Leuk Lymphoma; 2021 Aug; 62(8):1828-1839. PubMed ID: 33734005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.
    International CLL-IPI working group
    Lancet Oncol; 2016 Jun; 17(6):779-790. PubMed ID: 27185642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients.
    Molica S; Shanafelt TD; Giannarelli D; Gentile M; Mirabelli R; Cutrona G; Levato L; Di Renzo N; Di Raimondo F; Musolino C; Angrilli F; Famà A; Recchia AG; Chaffee KG; Neri A; Kay NE; Ferrarini M; Morabito F
    Am J Hematol; 2016 Nov; 91(11):1090-1095. PubMed ID: 27465919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia.
    Perbellini O; Falisi E; Giaretta I; Boscaro E; Novella E; Facco M; Fortuna S; Finotto S; Amati E; Maniscalco F; Montaldi A; Alghisi A; Aprili F; Bonaldi L; Paolini R; Scupoli MT; Trentin L; Ambrosetti A; Semenzato G; Pizzolo G; Rodeghiero F; Visco C
    Haematologica; 2014 May; 99(5):881-7. PubMed ID: 24415628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic significance of CLL-IPI for Chinese patients with chronic lymphocytic leukemia].
    Zhu HY; Wang L; Qiao J; Zou YX; Xia Y; Wu W; Cao L; Liang JH; Fan L; Xu W; Li JY
    Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):392-397. PubMed ID: 29779348
    [No Abstract]   [Full Text] [Related]  

  • 18. Variable expression of CD49d antigen in B cell chronic lymphocytic leukemia is related to disease stages.
    Eksioğlu-Demiralp E; Alpdoğan O; Aktan M; Firatli T; Oztürk A; Budak T; Bayik M; Akoğlu T
    Leukemia; 1996 Aug; 10(8):1331-9. PubMed ID: 8709639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia.
    Brachtl G; Piñón Hofbauer J; Greil R; Hartmann TN
    Ann Hematol; 2014 Mar; 93(3):361-74. PubMed ID: 24288111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the CLL-IPI and IPS-E Prognostic Indices in a Young Middle Eastern Population with Chronic Lymphocytic Leukemia: A Retrospective Analysis at the Kuwait Cancer Control Center.
    Alshemmari SH; Alsarraf A; Kunhikrishnan A; Pandita R
    Med Princ Pract; 2023; 32(3):192-199. PubMed ID: 37517397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.